Almitrine

Jump to: navigation, search
Almitrine
Almitrine.png
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC26H29F2N7
Molar mass477.552 g/mol
3D model (JSmol)
Melting point181 °C (357.8 °F)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Almitrine

Articles

Most recent articles on Almitrine

Most cited articles on Almitrine

Review articles on Almitrine

Articles on Almitrine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Almitrine

Images of Almitrine

Photos of Almitrine

Podcasts & MP3s on Almitrine

Videos on Almitrine

Evidence Based Medicine

Cochrane Collaboration on Almitrine

Bandolier on Almitrine

TRIP on Almitrine

Clinical Trials

Ongoing Trials on Almitrine at Clinical Trials.gov

Trial results on Almitrine

Clinical Trials on Almitrine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Almitrine

NICE Guidance on Almitrine

NHS PRODIGY Guidance

FDA on Almitrine

CDC on Almitrine

Books

Books on Almitrine

News

Almitrine in the news

Be alerted to news on Almitrine

News trends on Almitrine

Commentary

Blogs on Almitrine

Definitions

Definitions of Almitrine

Patient Resources / Community

Patient resources on Almitrine

Discussion groups on Almitrine

Patient Handouts on Almitrine

Directions to Hospitals Treating Almitrine

Risk calculators and risk factors for Almitrine

Healthcare Provider Resources

Symptoms of Almitrine

Causes & Risk Factors for Almitrine

Diagnostic studies for Almitrine

Treatment of Almitrine

Continuing Medical Education (CME)

CME Programs on Almitrine

International

Almitrine en Espanol

Almitrine en Francais

Business

Almitrine in the Marketplace

Patents on Almitrine

Experimental / Informatics

List of terms related to Almitrine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Almitrine (marketed as Duxil by Servier) is a diphenylmethylpiperazine derivative classified as a respiratory stimulant by the ATC. It enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep. A significant literature exists for this compound, including over 60 papers that Medline labels as reviews.

The clinical efficacy of almitrine-raubasine combination therapy for age related cerebral disorders and functional rehabilitation after stroke has been reviewed by Allain and Bentué-Ferrer.[1] They summarize two studies in which almitrine-raubasine improved some symptoms significantly more than placebo, especially in vascular cases. Their paper also suggests that other studies have shown a beneficial effect of this compound on neurosensory vascular disorders, specifically chorioretinal dysfunctions (visual symptomatology) and vertigo associated with electronystagmographic modifications. This paper further claims that the dosage and tolerance of the compound have been confirmed in a French multi-center study of 5,361 outpatients.


References

  1. Allain, H.; Bentué-Ferrer, D. (1998). "Clinical Efficacy of Almitrine-Raubasine". European Neurology. 39 (Suppl. 1): 39–44. doi:10.1159/000052069. PMID 9516074.

Linked-in.jpg